Inactive Instrument

IGEA Pharma N.V.

Equities

IGPH

NL0012768675

Medical Equipment, Supplies & Distribution

IGEA Pharma N : ensures ‘Alz1’ supply for the EU market

December 06, 2020 at 03:45 pm EST

Hoofddorp, the Netherlands, 6 December 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the signature of an agreement with CSM Europe for the 'CE' compliant supply of Alz1. The distribution of Alz1 on a wholesale basis in selected EU markets is expected to start within the first half of 2021.

Attachments

Original document
Permalink

Disclaimer

IGEA Pharma NV published this content on 06 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 December 2020 20:44:07 UTC

Latest news about IGEA Pharma N.V.

Igea Pharma to Delist from SIX Swiss Exchange	Dec. 19	MT
Swiss Market Index Flat Amid Expected Labor Market Growth	Nov. 06	MT
Appeals Board Upholds Decision to Delist IGEA Pharma from SIX Swiss Exchange on Questionable Solvency	Nov. 06	MT
IGEA Pharma to Merge Divisions With RBCARE2023	23-10-04	MT
IGEA Pharma Swings to H1 Profit	23-10-02	MT
IGEA Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-30	CI
IGEA Pharma Appeals Delisting Notice from SIX Swiss Exchange	23-08-31	MT
IGEA Pharma to Delist from SIX Swiss Exchange in November	23-08-03	MT
IGEA Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	23-07-30	CI
Achiko, IGEA, Talenthouse Shares Suspended from Trading on SIX Swiss Exchange	23-06-01	MT
IGEA Pharma Seeks Deadline Extension for FY22 Annual Report Publication	23-06-01	MT
IGEA Pharma to Divest Industrial Process Business in Refocusing Move	23-05-30	MT
IGEA Pharma Receives Fine for Breach of Listing Rules	23-04-13	MT
IGEA Pharma's H1 Loss Shrinks Amid Lower Expenses	22-10-31	MT
IGEA Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-30	CI
IGEA Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2021	22-10-19	CI
Swiss Exchange Regulator Investigates IGEA Pharma For Violating Reporting Rules	22-09-02	MT
IGEA Pharma Suspends Trading Amid Delayed FY21 Annual Report	22-08-02	MT
IGEA Pharma Close to Finalizing $6 Million Investment Deal For Cannabidiol Extraction Facility	22-07-12	MT
Igea Pharma Secures $6 Million Funds To Complete Cannabidiol Extraction Facility	22-06-08	MT
IGEA Pharma Gets Swiss Bourse Approval To Delay FY21 Annual Report Publication	22-05-02	MT
IGEA Pharma N : H1 Loss Narrows on Gains From Financial Liabilities, Sale of Assets	21-10-01	MT
IGEA Pharma N.V. Reports Earnings Results for First Half 2021	21-09-30	CI
Igea Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-30	CI
IGEA Pharma N : Expects Earnings, Revenue Boost On Blue Sky Natural Resources Deal	21-08-02	MT

Chart IGEA Pharma N.V.

Duration

Period

More charts

Company Profile

IGEA Pharma NV is a biopharmaceutical company based in the Netherlands. The Company focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The Company develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer's disease. The Company offers its services in the Netherlands.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-11 - Q4 2023 Earnings Release (Projected)

More about the company

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOMÉRIEUX	-1.89%	12.56B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-9.59%	7.68B
DIASORIN S.P.A.	-1.31%	5.29B
LANTHEUS HOLDINGS, INC.	+21.82%	5.18B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.02%	4.57B
10X GENOMICS, INC.	-50.89%	3.29B
ANDON HEALTH CO., LTD.	+6.42%	2.6B
VITROLIFE AB	-10.02%	2.2B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-8.29%	1.79B

Diagnostic & Testing Substances